The use of DOACs in patients with cancer-associated venous thrombosis ...

should be the standard of care (aka first line option)
19% (4 votes)
an attractive alternative to LWMHs but not first line
57% (12 votes)
might be considered in some limited circumstances
19% (4 votes)
are still a experimental therapy and used only in a clinical trial.
5% (1 vote)
Total votes: 21